Nuno Vau
23 Papers
42 Citations
Nuno Vau is an academic researcher. The author has contributed to research in topics: Internal medicine & Medicine. The author has an hindex of 5, co-authored 10 publications.
Chat about Author
Papers
Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer
Antonio Lopez-Beltran,Alessia Cimadamore,Ana Blanca,Francesco Massari,Nuno Vau,Marina Scarpelli,Liang Cheng,Rodolfo Montironi +7 more
TL;DR: In this article, the authors examined relevant clinical trial results with ICIs in patients with metastatic urothelial carcinoma (mUC) alone or as part of drug combinations; emphasis is also placed on the adjuvant and neoadjuvant setting.
213
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
Matteo Santoni,Sebastiano Buti,Zin W. Myint,Marco Maruzzo,Roberto Iacovelli,Martin Pichler,Jindřich Kopecký,Jakub Kucharz,Mimma Rizzo,Luca Galli,Thomas Büttner,Ugo De Giorgi,Ravindran Kanesvaran,Ondrej Fiala,Enrique Grande,Paolo Andrea Zucali,R. M. Kopp,Giuseppe Fornarini,Maria T Bourlon,Sarah Scagliarini,Javier Molina-Cerrillo,Gaetano Aurilio,Marc R. Matrana,Renate Pichler,Carlo Cattrini,Tomáš Büchler,Francesco Massari,Emmanuel Seront,Fabio Calabrò,Alvaro Pinto,Rossana Berardi,A. N. Zgura,Giulia Mammone,Jawaher Ansari,Francesco Atzori,Rita Chiari,Aristotelis Bamias,Orazio Caffo,Giuseppe Procopio,Kaisa L. Sunela,Maria Bassanelli,Cinzia Ortega,Francesco Grillone,John A. Landmesser,Michele Milella,Carlo Messina,Zsófia Küronya,Alessandra Mosca,Dipen Bhuva,Daniele Santini,Nuno Vau,Franco Morelli,Lorena Incorvaia,Sara Elena Rebuzzi,Giandomenico Roviello,Andrey Soares,R. Bisonni,Davide Bimbatti,I. Zabalza,Alessandro Rizzi,Veronica Mollica,Giulia Sorgentoni,Fernando Sabino Marques Monteiro,Nicola Battelli,Sergio Bracarda,Camillo Porta +65 more
TL;DR: A clear association with longer PFS and OS in favor of patients who received the IO + TKI combinations compared with the IO-IO combination was observed, and found in real-life data that intermediate-risk patients are found to benefit more from the immunotherapy-+ antiangiogenic therapy than double immunotherapy patients.
23
Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
Matteo Santoni,Francesco Massari,Zin W. Myint,Roberto Iacovelli,Martin Pichler,Umberto Basso,Jindřich Kopecký,Jakub Kucharz,Sebastiano Buti,Mimma Rizzo,Luca Galli,Thomas Büttner,Ugo De Giorgi,Ravindran Kanesvaran,Ondrej Fiala,Enrique Grande,Paolo Andrea Zucali,Giuseppe Fornarini,Maria T Bourlon,Sarah Scagliarini,Javier Molina-Cerrillo,Gaetano Aurilio,Marc R. Matrana,Renate Pichler,Carlo Cattrini,Tomáš Büchler,Emmanuel Seront,Fabio Calabrò,Alvaro Pinto,Rossana Berardi,Anca Zgura,Giulia Mammone,Jawaher Ansari,Francesco Atzori,Rita Chiari,Aristotelis Bamias,Orazio Caffo,Giuseppe Procopio,Maria Bassanelli,Sara Merler,Carlo Messina,Zsófia Küronya,Alessandra Mosca,Dipen Bhuva,Nuno Vau,Lorena Incorvaia,Sara Elena Rebuzzi,Giandomenico Roviello,I. Zabalza,A. Rizzo,Veronica Mollica,Giulia Sorgentoni,Fernando Sabino Marques Monteiro,Rodolfo Montironi,Nicola Battelli,Camillo Porta +55 more
TL;DR: This study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.
20
Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1).
Matteo Santoni,Francesco Massari,Zin W. Myint,Roberto Iacovelli,Martin Pichler,Umberto Basso,Jindřich Kopecký,Jakub Kucharz,Sebastiano Buti,A. Salfi,Thomas Büttner,Ugo De Giorgi,Ravindran Kanesvaran,Ondrej Fiala,Enrique Grande,Paolo Andrea Zucali,Giuseppe Fornarini,Maria T Bourlon,Sarah Scagliarini,Javier Molina-Cerrillo,Gaetano Aurilio,Marc R. Matrana,Renate Pichler,Carlo Cattrini,Tomáš Büchler,Emmanuel Seront,Fabio Calabrò,Alvaro Pinto,Rossana Berardi,A. N. Zgura,Giulia Mammone,Jawaher Ansari,Francesco Atzori,Rita Chiari,Roubini Zakopoulou,Orazio Caffo,Giuseppe Procopio,Maria Bassanelli,Ilaria Zampiva,Carlo Messina,Zsófia Küronya,Alessandra Mosca,Dipen Bhuva,Nuno Vau,Lorena Incorvaia,Sara Elena Rebuzzi,Giandomenico Roviello,I. Zabalza,Alessandro Rizzi,Veronica Mollica,Ilaria Catalini,Fernando Sabino Marques Monteiro,Rodolfo Montironi,Nicola Battelli,Mimma Rizzo,Camillo Porta +55 more
TL;DR: The role of body mass index (BMI) in patients from the ARON-1 study (NCT05287464) treated by dual immuno-oncology agents (IO+IO) or a combination of immunotherapy drug and a tyrosine kinase inhibitors (TKI) as first-line therapy for metastatic renal cell carcinoma (mRCC) was investigated in this article .
13
Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
Matteo Santoni,Francesco Massari,Sergio Bracarda,Giuseppe Procopio,Michele Milella,Ugo De Giorgi,Umberto Basso,Gaetano Aurilio,Lorena Incorvaia,Angelo Martignetti,Mimma Rizzo,Giacomo Cartenì,Enrique Grande,Marc R. Matrana,Simon J. Crabb,Nuno Vau,Giulia Sorgentoni,Alessia Cimadamore,Rodolfo Montironi,Nicola Battelli +19 more
- 18 Jan 2021
TL;DR: In this paper, the clinical and pathological features of renal cell carcinoma (RCC) patients treated with cabozantinib stratified by body mass index (BMI) were analyzed using Kaplan-Meier curves.